

IAP9 Rec'd PCT/PTO 10/559675
6 DEC 2005

10559675 - GAU: 1626

Patent
Docket No. 130-PCT-US

IN THE UNITED STATE PATENT AND TRADE MARK OFFICE

Applicant: James Jaquith et al Art unit: Not yet assigned
Serial No: Not yet Assigned Examiner: Not yet assigned
Filed: Customer No:
Title: **Acylated and Non-acylated Imidazo[2,1-b]-1,3,4-Thiadiazole-2-Sulfonamides, and Uses Thereof**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia
USA 22313-1450


INFORMATION DISCLOSURE STATEMENT

This statement is being filed with the application. Applicants submit the enclosed PTO 1449 form identifying four (4) references. Under 35 USC § 120, this application relies on the earlier filing date of application serial number PCT-CA2004/000873 filed June 14, 2004.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Respectfully submitted,

Date: December 2, 2005.


Philip A. Swain, Ph.D.
Registration No: 55,978

Dr. Philip A. Swain
c/o Aegera Therapeutics Inc
810 Chemin du Golf
Nun's Island, Quebec
Canada H3E 1A8
Telephone : (514) 288 – 4091 Ext :353
Facsimile: (514) 288 - 9820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	PCT/CA2004/000873
Sheet	2	of	2	Filing Date	
				First Named Inventor	James Jaquith
				Art Unit	
				Examiner Name	
				Attorney Docket Number	130-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./		ANDNAPPA, K. et al. Synthesis and biological evaluation(dimethylamino)meth. Arzneimittel Forshung, Drug Research, Editio Cantor, Aulendorf, De vol.49,no. 10:858-863.	
/K.S./		TALLEY, J.J. et al. "N-``(5-Methyl-3-phenylisoxazol-4-yl)-phenyl!.Journal of Medicinal Chemistry, American Chemical Society, Washington, US. vol 43, no.9, May 2000:1661-1663	

Examiner Signature	/Kamal Saeed/	Date Considered	03/01/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/559675

IAP9 Rec'd PCT/PTO 06 DEC 2005
PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

Approved for use through 07/01/2006. GMB 0851-0851
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	PCT/CA2004/000873
Filing Date	
First Named Inventor	James Jaquith
Art Unit	
Examiner Name	
Attorney Docket Number	130-PCT-US

Sheet 1 of 2

Attorney Docket Number 130-PCT-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	FOREIGN PATENT DOCUMENTS		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Foreign Patent Document	Publication Date MM-DD-YYYY			
/K.S./		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/K.S./		GB 1 464 259 A	09 02 1977	Pfizer Ltd		
/K.S./		WO 03/051590 A	06 26 2003	Aegera Therapeutics Inc		

Examiner Signature	/Kamal Saeed/	Date Considered	03/01/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.